NCT03908567View on ClinicalTrials.gov

AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

March 28, 2022

Study Completion Date

March 28, 2022

Conditions
Vestibular Vertigo
Interventions
DRUG

Intranasal Drug

Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day

DRUG

Oral Tablet

Oral dosing with tablets 3 times a day

OTHER

Intranasal Placebo

Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day

Trial Locations (1)

Unknown

CHP Clairval, Marseille

Sponsors

Lead Sponsor

Auris Medical AG
All Listed Sponsors
lead

Auris Medical AG

INDUSTRY

NCT03908567 - AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery | Biotech Hunter | Biotech Hunter